A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Recruiting · NCT07383506 · Registry updated 2026-08-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, skin disorder, uterine disorder | Recruiting | Phase 1 | 2026-08-26 | NCT07383506 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cogent Biosciences, Inc. | 7 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. | Tampa | United States | 4 |
| HonorHealth Research Institute | Scottsdale | United States | 36 |
| NEXT Austin | Austin | United States | 10 |
| NEXT Virginia | Fairfax | United States | 83 |
| Sarah Cannon Research Institute (SCRI) at HealthONE-Denver | Denver | United States | 1 |
| SCRI Oncology Partners - Nashville | Nashville | United States | 1 |
| START Los Angeles | Los Angeles | United States | 14 |
| START Mountain Region, LLC | West Valley City | United States | 5 |
| START New Jersey, LLC | East Brunswick | United States | 1 |
| Washington University School of Medicine - Siteman Cancer Center | St Louis | United States | 19 |